Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NSPR Stock Forecast 2026-2027
$1.59
Current Price
$66.10M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NSPR Price Targets
+214.5%
To High Target of $5.00
+183.0%
To Median Target of $4.50
+151.6%
To Low Target of $4.00
NSPR Price Momentum
-13.6%
1 Week Change
-19.3%
1 Month Change
-40.7%
1 Year Change
-10.7%
Year-to-Date Change
-58.2%
From 52W High of $3.80
+5.3%
From 52W Low of $1.51
📊 TOP ANALYST CALLS
Did NSPR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if InspireMD is one of their latest high-conviction picks.
Latest NSPR Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, NSPR has a bullish consensus with a median price target of $4.50 (ranging from $4.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.59, the median forecast implies a 183.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 214.5% upside. Conversely, the most conservative target is provided by Adam Maeder at Piper Sandler, suggesting a 151.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NSPR Analyst Ratings
2
Buy
0
Hold
0
Sell
NSPR Price Target Range
Low
$4.00
Average
$4.50
High
$5.00
Current: $1.59
Latest NSPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NSPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | Piper Sandler | Adam Maeder | Overweight | Maintains | $4.00 |
| Dec 11, 2024 | Lake Street | Frank Takkinen | Buy | Initiates | $5.00 |
| Sep 17, 2024 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $4.50 |
| Nov 2, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $4.50 |
| Jun 12, 2023 | Piper Sandler | Adam Maeder | Overweight | Initiates | $3.00 |
| May 17, 2023 | National Alliance Securities | Ben Haynor | Buy | Maintains | $4.75 |
| Mar 31, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $5.15 |
| Oct 16, 2020 | Alliance Global Partners | Ben Haynor | Buy | Initiates | $0.70 |
| Mar 11, 2020 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Mar 29, 2016 | Rodman & Renshaw | Buy | Maintains | $3.00 |
InspireMD Inc. (NSPR) Competitors
The following stocks are similar to InspireMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InspireMD Inc. (NSPR) Financial Data
InspireMD Inc. has a market capitalization of $66.10M with a P/E ratio of -2.1x. The company generates $7.78M in trailing twelve-month revenue with a 21.5% profit margin.
Revenue growth is +39.4% quarter-over-quarter, while maintaining an operating margin of -517.3% and return on equity of -87.6%.
Valuation Metrics
Market Cap
$66.10M
Enterprise Value
$8.61M
P/E Ratio
-2.1x
PEG Ratio
-0.3x
Price/Sales
8.4x
Growth & Margins
Revenue Growth (YoY)
+39.4%
Gross Margin
+34.2%
Operating Margin
-517.3%
Net Margin
+21.5%
EPS Growth
+39.4%
Financial Health
Cash/Price Ratio
+94.1%
Current Ratio
6.5x
Debt/Equity
5.3x
ROE
-87.6%
ROA
-45.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InspireMD Inc. (NSPR) Business Model
About InspireMD Inc.
What They Do
Develops innovative embolic prevention medical devices.
Business Model
InspireMD Inc. generates revenue through the development and distribution of its proprietary embolic prevention systems and neurovascular devices, particularly focusing on enhancing the safety and efficacy of vascular procedures. By targeting severe cardiovascular conditions, the company seeks to capture a significant share of the interventional cardiology and neurovascular markets globally.
Additional Information
Headquartered in Tel Aviv, Israel, InspireMD serves a worldwide market and emphasizes reducing risks associated with stenting, such as embolization and restenosis. The company's commitment to advancing medical technology positions it as a crucial player in the healthcare innovation landscape.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
66
CEO
Mr. Marvin L. Slosman
Country
United States
IPO Year
2011
Website
www.inspiremd.comInspireMD Inc. (NSPR) Latest News & Analysis
Latest News
Quick Summary
InspireMD's CGuard® Prime carotid stent system showed the lowest 30-day and 1-year adverse event rates in pivotal trials. Results published in JACC confirm its safety and efficacy for stroke prevention.
Why It Matters
CGuard® Prime's impressive safety data enhances InspireMD's market position, potentially increasing demand and revenues, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Carotid artery stenting with medical therapy significantly reduced stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis.
Why It Matters
The study's findings may boost demand for carotid artery stenting devices, positively impacting companies in the medical device sector and potentially driving stock prices higher.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InspireMD, Inc. approved inducement grants of 122,054 restricted stock shares to eight new non-executive employees, effective November 20, 2025, outside its 2021 Equity Incentive Plan.
Why It Matters
The approval of stock grants for new employees can signal company growth and stability, potentially boosting investor confidence in InspireMD's future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InspireMD, Inc. (NSPR) will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:30 PM ET.
Why It Matters
InspireMD's participation in a prominent healthcare conference may enhance visibility, attract investors, and signal confidence in its CGuard® Prime stent system's market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
InspireMD, Inc. (NSPR) will hold its Q3 2025 earnings call on November 4, 2025, at 8:30 AM EST, featuring key executives and analysts from Piper Sandler and Lake Street Capital.
Why It Matters
Earnings calls provide insights into a company's financial health and future outlook, impacting stock performance and investor sentiment. Key executives' comments can influence investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CGuard Prime's successful U.S. commercial launch has resulted in record quarterly revenue.
Why It Matters
The successful CGuard Prime launch indicates strong market demand, potentially boosting future revenue and profitability, which could enhance stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NSPR Stock
What is InspireMD Inc.'s (NSPR) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, InspireMD Inc. (NSPR) has a median price target of $4.50. The highest price target is $5.00 and the lowest is $4.00.
Is NSPR stock a good investment in 2026?
According to current analyst ratings, NSPR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NSPR stock?
Wall Street analysts predict NSPR stock could reach $4.50 in the next 12 months. This represents a 183.0% increase from the current price of $1.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InspireMD Inc.'s business model?
InspireMD Inc. generates revenue through the development and distribution of its proprietary embolic prevention systems and neurovascular devices, particularly focusing on enhancing the safety and efficacy of vascular procedures. By targeting severe cardiovascular conditions, the company seeks to capture a significant share of the interventional cardiology and neurovascular markets globally.
What is the highest forecasted price for NSPR InspireMD Inc.?
The highest price target for NSPR is $5.00 from Frank Takkinen at Lake Street, which represents a 214.5% increase from the current price of $1.59.
What is the lowest forecasted price for NSPR InspireMD Inc.?
The lowest price target for NSPR is $4.00 from Adam Maeder at Piper Sandler, which represents a 151.6% increase from the current price of $1.59.
What is the overall NSPR consensus from analysts for InspireMD Inc.?
The overall analyst consensus for NSPR is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are NSPR stock price projections?
Stock price projections, including those for InspireMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:46 AM UTC